[ Frequency Therapeutics raises $32M in Series A ]
Frequency Therapeutics has raised $32 million in Series A funding.
Founded in 2015, Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering.
New funding supports expanded work to realize the disease modifying potential of Progenitor Cell Activation (PCA™) beyond hearing loss.
|Founder / CEO||David L. Lucchino|
|Alexandria Real Estate Equities|
|Korea Investment Partners|